



# Impact of HbA<sub>1c</sub>, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden)

Maria Nordwall,<sup>1</sup> Mariann Abrahamsson,<sup>2</sup> Meryl Dhir,<sup>2</sup> Mats Fredrikson,<sup>3</sup> Johnny Ludvigsson,<sup>4</sup> and Hans J. Arnqvist<sup>5</sup>

*Diabetes Care* 2015;38:308–315 | DOI: 10.2337/dc14-1203

## OBJECTIVE

HbA<sub>1c</sub> is strongly related to the development of diabetes complications, but it is still controversial which HbA<sub>1c</sub> level to strive for in the treatment of type 1 diabetes. The aim of the current study was to evaluate HbA<sub>1c</sub>, followed from diagnosis, as a predictor of severe microvascular complications and to formulate HbA<sub>1c</sub> target levels for treatment.

## RESEARCH DESIGN AND METHODS

A longitudinal observation study followed an unselected population of 451 patients diagnosed with type 1 diabetes during 1983–1987 before the age of 35 years in a region of Southeast Sweden. Retinopathy was evaluated by fundus photography and nephropathy data collected from medical records. HbA<sub>1c</sub> was measured starting from diagnosis and during the whole follow-up period of 20–24 years. Long-term weighted mean HbA<sub>1c</sub> was then calculated. Complications were analyzed in relation to HbA<sub>1c</sub> levels.

## RESULTS

The incidence of proliferative retinopathy and persistent macroalbuminuria increased sharply and occurred earlier with increasing long-term mean HbA<sub>1c</sub>. None of the 451 patients developed proliferative retinopathy or persistent macroalbuminuria below long-term weighted mean HbA<sub>1c</sub> 7.6% (60 mmol/mol); 51% of the patients with long-term mean HbA<sub>1c</sub> above 9.5% (80 mmol/mol) developed proliferative retinopathy and 23% persistent macroalbuminuria.

## CONCLUSIONS

Long-term weighted mean HbA<sub>1c</sub>, measured from diagnosis, is closely associated with the development of severe complications in type 1 diabetes. Keeping HbA<sub>1c</sub> below 7.6% (60 mmol/mol) as a treatment target seems to prevent proliferative retinopathy and persistent macroalbuminuria for up to 20 years.

<sup>1</sup>Department of Pediatrics and Department of Clinical and Experimental Medicine, Linköping University, Norrköping, Sweden

<sup>2</sup>Department of Ophthalmology and Department of Clinical and Experimental Medicine, Linköping University, Norrköping, Sweden

<sup>3</sup>Division of Occupational and Environmental Medicine, Department of Clinical and Experimental Medicine, and Linköping Academic Research Centre, Linköping University, Linköping, Sweden

<sup>4</sup>Department of Pediatrics and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

<sup>5</sup>Department of Endocrinology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

Corresponding author: Maria Nordwall, maria.nordvall@lio.se.

Received 12 May 2014 and accepted 29 October 2014.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-1203/-/DC1>.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Glycosylated hemoglobin (HbA<sub>1c</sub>) was proposed as a long-term measure of average glycemia and introduced into clinical practice in the early 1980s (1). HbA<sub>1c</sub> may reflect a pathogenic mechanism of glucose metabolism in diabetes complications, as it mirrors glycosylation of proteins (2). The Diabetes Control and Complications Trial (DCCT) and other interventional studies have convincingly demonstrated the importance of near-normal glycemic control, measured as HbA<sub>1c</sub>, to prevent long-term microvascular complications in both type 1 and type 2 diabetes (3–6). The crucial role of good glycemic control is also shown in unselected population studies (7–9).

Since advanced diabetes complications, especially nephropathy, appear first after 15–20 years of diabetes duration (10,11), it has not until now been possible to study complications with a reliable measurement of glycemic control from diabetes onset. Besides glycemic control and diabetes duration, there is evidence that age at onset influences the development of microangiopathy (12). Children seem to be protected from severe microvascular complications before puberty, but the effect seems to disappear with time (13). A sufficiently long follow-up is therefore necessary to evaluate the importance of glycemic control, especially in childhood-onset diabetes.

There is still controversy as to how strict glycemic control should be to avoid severe complications (14,15). In clinical practice, it is of great importance to find the right balance between the risk for severe microvascular complications, potentially dangerous hypoglycemic events, and quality of life and to be able to recommend an optimal level of HbA<sub>1c</sub> both in the short and long term. The aim with this study was to evaluate HbA<sub>1c</sub>, followed from diagnosis, as a biomarker for risk of developing severe microvascular diabetes complications and to formulate HbA<sub>1c</sub> target levels for treatment.

## RESEARCH DESIGN AND METHODS

### Patients

All 451 patients with type 1 diabetes diagnosed during 1983–1987 in Southeast Sweden were included. They had a clinical picture of type 1 diabetes before the age of 35 years and insulin treatment <6 months from diagnosis as described earlier (12). The patients received routine

care. They were identified using local registers and validated with the help of the Swedish Childhood Diabetes Registry and the Diabetes Incidence Study in Sweden (DISS). Of the original cohort of 440 patients (12), 8 patients were shown to have type 2 diabetes and other types of diabetes, while 19 patients were added from Swedish Childhood Diabetes Registry; 58% were male and 42% female; 54% were diagnosed before the age of 15 years.

The 10-digit personal identity number, unique to Sweden, made it possible to track the patients. Data were retrospectively collected in the patients' records or by their physicians, using a questionnaire. Most of the patients were followed until 2005–2008. Mean (SD) duration at follow-up was 22.1 (2.0) years. For 17 patients, it was not possible to track data for the whole period of time; 11 patients were deceased, and 6 patients had moved abroad.

The Research Ethics Committee of the Faculty of Health Sciences, Linköping University, approved the study.

### Blood Pressure, Blood Lipids, and BMI

At the last follow-up date, data about blood pressure, blood lipids, height, and weight were collected from the patients' records as well as data about antihypertensive and lipid-lowering treatment.

For the whole population (data were stated as mean ± SD). BMI was 26.1 ± 4.3 kg/m<sup>2</sup>, total cholesterol was 4.7 ± 1.0 mmol/L (181.5 ± 38.6 mg/dL), triglycerides were 1.2 ± 0.9 mmol/L (106.2 ± 79.6 mg/dL), systolic blood pressure was 124 ± 16 mmHg, and diastolic blood pressure was 74 ± 8 mmHg. BMI was significantly higher in patients with more advanced forms of retinopathy (moderate simplex and proliferative retinopathy), and triglycerides were significantly higher in patients with micro- and macroalbuminuria. Systolic blood pressure was significantly higher in patients with microalbuminuria and macroalbuminuria, and diastolic blood pressure was significantly higher in patients with microalbuminuria. The other associations were not statistically significant, but there was a trend to higher blood pressure and lipid values in patients with microvascular complications. Detailed data about BMI, lipids, and blood pressure are given in Supplementary Tables 1 and 2.

Of all patients, 27% had antihypertensive treatment at follow-up. Of these, 87% used an ACE inhibitor (67%) or

angiotensin II receptor blockers (20%). Five percent had antihypertensive medication and previous microalbuminuria but were now normoalbuminuric. For 42%, the indication of antihypertensive treatment was hypertension with no signs of micro- or macroalbuminuria before onset of treatment. Seventy-two percent of the patients with antihypertensive treatment had no signs of proliferative retinopathy. In total, 14 and 23% had antihypertensive treatment without any signs of nephropathy or proliferative retinopathy, respectively. Lipid-lowering agents, in almost all cases, statins, were used in 28% of the patients.

### HbA<sub>1c</sub> Measurement

HbA<sub>1c</sub> was measured regularly at the clinical visits, 2–4 times per year, and analyzed by local hospital laboratories. At the start of the study in January 1983, HbA<sub>1c</sub> was analyzed by Isolab minicolumns (Fast Hb Test System, Isolab Inc., Akron, OH) at the four central laboratories. This was replaced during 1984–1987 by high-performance liquid chromatography methods measuring HbA<sub>1c</sub> with high precision. The analyzing laboratories calculated intermethod calibrations and conversion factors when the methods were changed. From June 1994, hospital laboratories were participating in an interlaboratory quality program (Equalis, Uppsala, Sweden), where all laboratories analyzed two samples per month. In 1997, a nationwide standardization was introduced, and repeated comparisons were made with National Glycohemoglobin Standardization Program (NGSP) values, which showed the Swedish values to be 1.1% lower than NGSP values (16). The same was demonstrated in a study comparing HbA<sub>1c</sub> measured in 1994 at the Linköping Hospital Laboratory with the DCCT laboratory (17). All values are converted by formulas to the new International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference values. The corresponding NGSP values are also stated, making it possible to compare the results with previous studies. The conversion formula is HbA<sub>1c</sub> (NGSP) (%) = 0.0915 × HbA<sub>1c</sub> (IFCC) (mmol/mol) + 2.153. The normal range is 27–42 mmol/mol (IFCC) corresponding to 4.6–6.0% (NGSP) (18). For many of the patients who moved, it has been possible to obtain their HbA<sub>1c</sub>

values from their physicians, and conversions factors to the Equalis reference method was done by the local laboratory. However, 90% of the HbA<sub>1c</sub> values come from laboratories in the catchment area. As a measure of long-term glycemic control, long-term mean HbA<sub>1c</sub> was calculated and weighted for the time between the measurements (wHbA<sub>1c</sub>) (19). All HbA<sub>1c</sub> values, from diabetes diagnosis and until the year of laser therapy, onset of persistent macroalbuminuria, or last follow-up time were used for the calculations. For statistical analysis, wHbA<sub>1c</sub> was divided into five different classes. For some analyses, it was necessary to combine categories because of the absence of readings in the lowest categories.

**Retinopathy**

Retinal screening using color fundus photography was planned every other year for each patient from the onset of diabetes or from 10 years of age. Three standard photographs were taken, after pupil dilation, of each eye: nasal to the optic nerve, the optic nerve and macula, and temporal to the macula. The prevalence of retinopathy was calculated by reevaluation of fundus photos taken between 2005 and 2008. If no photo was available during this period, the last photo, closest to these dates, was selected. The duration of diabetes at the date of photography was mean (SD) 20.8 (2.9) years. The date of the first laser treatment was collected from clinical records. Photographs or reliable

data concerning previous laser therapy for proliferative retinopathy or maculopathy were available for 431 (96%) patients. Eleven patients had died, six patients had moved abroad, and three patients had not participated in screening. Two ophthalmologists (M.A. and M.D.) evaluated the photographs independently. The photographs were graded according to the Modified Airlie House protocol and grouped according to the worst eye into four classes: normal, slight simplex, moderate simplex, and proliferative retinopathy or maculopathy (or previous laser therapy) (20). If the grading was dissimilar, the ophthalmologists reevaluated the photos and then together decided the grading. The incidence of severe retinopathy, defined as the date of the first laser treatment for proliferative retinopathy or maculopathy, was also calculated.

**Nephropathy**

The patients were screened for proteinuria at their regular clinical visits, at least once every year. The urine sample was analyzed at the local hospital laboratory with quantitative immunoturbidometric methods, either as a timed overnight analysis or as a morning spot test.

Microalbuminuria was defined as an albumin excretion rate (AER) 20–200 µg/min or albumin/creatinine ratio of 3–30 mg/mmol. Macroalbuminuria was defined as an AER >200 µg/min or albumin/creatinine ratio >30 mg/mmol. For all patients with macroalbuminuria,

the medical records were scrutinized to confirm that there was no other kidney disease explaining the condition. Data were available for 420 (93%) of the patients.

The prevalence of nephropathy was examined at the last follow-up and grouped as normoalbuminuria, microalbuminuria, or persistent macroalbuminuria. The 23 patients who were normoalbuminuric but treated with ACE inhibitors because of previous microalbuminuria were classified as microalbuminuria. In calculating the incidence of macroalbuminuria, the first year when macroalbuminuria became persistent was indicated as onset.

**Statistical Analysis**

Differences between groups were tested using *t* test or ANOVA with a post hoc Bonferroni test. Frequencies were compared using  $\chi^2$  tests. Life table analysis with Wilcoxon (Gehan) log-rank test was used for analysis of incidence of retinopathy and persistent macroalbuminuria.

The significance level was set as *P* < 0.05. SPSS version 21 was used for the analyses.

**RESULTS**

**HbA<sub>1c</sub>**

In total, 24,640 HbA<sub>1c</sub> values were collected, mean (SD) 54.9 (17.6) values per patient. For less than 6%, there was a gap of more than 2 years between measurements. Mean wHbA<sub>1c</sub> was 8.2% (95% CI 8.1–8.3%) (66 [65–67] mmol/mol) without sex difference. Distribution of wHbA<sub>1c</sub> is presented in Table 1. Only

**Table 1—Prevalence of microvascular complications in different HbA<sub>1c</sub> categories and long-term weighted mean HbA<sub>1c</sub> in an unselected population of patients with type 1 diabetes after 20–24 years of diabetes duration**

	Prevalence in various HbA <sub>1c</sub> categories NGSP values % (IFCC value mmol/mol)					Long-term weighted mean HbA <sub>1c</sub>			
	≤6.7 (≤50)	6.8–7.6 (51–60)	7.7–8.6 (61–70)	8.6–9.5 (71–80)	>9.5 (>80)	All		NGSP value % mean (95% CI)	IFCC value mmol/mol mean (95% CI)
	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>	%		
<b>Retinopathy</b>									
None	20	18	13	3	0	54	12.5	7.2 (6.9–7.4)	55 (52–58)
Mild simplex	16	56	46	23	4	145	33.6	7.8 (7.7–8.0)	62 (60–64)
Moderate simplex	1	39	69	46	19	174	40.4	8.4 (8.3–8.6)	68 (67–70)
Proliferative/laser therapy	0	1	14	19	24	58	13.5	9.4 (9.1–9.7)	79 (76–83)
All	37	114	142	91	47	431		8.2 (8.1–8.3)	66 (65–67)
<b>Nephropathy</b>									
Normoalbuminuria	30	102	119	64	25	340	81.0	8.0 (7.9–8.2)	64 (63–66)
Microalbuminuria	3	9	19	20	12	63	15.0	8.6 (8.3–8.9)	71 (68–74)
Macroalbuminuria	0	0	2	4	11	17*	4.0	10.1 (9.5–10.6)	86 (80–93)
All	33	111	140	88	48	420		8.2 (8.1–8.3)	66 (65–67)

*P* < 0.001 for HbA<sub>1c</sub> and grade of retinopathy and nephropathy. Data were analyzed using one-way ANOVA and Bonferroni post hoc test. All differences were significant in pairwise comparisons, apart from normoalbuminuria compared with microalbuminuria. \*Three patients had end-stage renal disease: two patients had kidney transplantation; one patient had long-term dialysis.

35% had wHbA<sub>1c</sub> lower than 7.1% (61 mmol/mol).

**Retinopathy**

The prevalence of different grades of retinopathy and relation to wHbA<sub>1c</sub> is shown in Table 1 and Figs. 1A and 2A. Only 12.5% of the patients had no signs of retinopathy, and 13.5% had laser-treated retinopathy. The indication for laser treatment was in all cases proliferative retinopathy, and all patients with proliferative retinopathy were laser treated. There were no cases of maculopathy.

Almost all patients had developed some grade of retinopathy except for the group with HbA<sub>1c</sub> ≤6.7% (50 mmol/mol). In this group, half of the patients had no retinopathy, and none were laser treated.

As shown in Fig. 2A the prevalence of laser-treated retinopathy increases sharply with increasing HbA<sub>1c</sub> levels, and in the group with HbA<sub>1c</sub> >9.5% (80 mmol/mol), half of the patients were laser treated. In the HbA<sub>1c</sub> categories ≤7.6% (60 mmol/mol), only one patient had been laser treated after

15 years of diabetes duration and with wHbA<sub>1c</sub> 7.6% (60 mmol/mol) (Fig. 2A). The cumulative proportion of laser treatment was higher and occurred earlier with increasing HbA<sub>1c</sub> levels (Fig. 3A).


**Nephropathy**

As shown in Table 1 and Figs. 1B and 2B, of 420 patients evaluated for nephropathy, 63 (15%) had microalbuminuria according to our definition and 17 (4%) macroalbuminuria. While cases with microalbuminuria were found at all levels of wHbA<sub>1c</sub>, macroalbuminuria was found only in the categories with HbA<sub>1c</sub> levels above 7.6% (60 mmol/mol) starting at a wHbA<sub>1c</sub> of 8.4% (68 mmol/mol). Of the 12 patients categorized as microalbuminuria in the groups with wHbA<sub>1c</sub> ≤7.6% (60 mmol/mol), 5 had reverted to normal and 5 had only marginally elevated AER after ACE-inhibitor therapy. There were highly significant differences in HbA<sub>1c</sub> levels between the various groups of albuminuria (Table 1 and Fig. 1B). The prevalence of macroalbuminuria increased sharply with higher HbA<sub>1c</sub> levels being 23% at HbA<sub>1c</sub> >9.5% (80 mmol/mol) (Fig. 2B). The cumulative proportion of persistent macroalbuminuria was increasing after ~15 years of diabetes duration (Fig. 3B). Two patients in HbA<sub>1c</sub> category 7.7–8.6% (61–70 mmol/mol) developed macroalbuminuria after 18 and 17 years of diabetes duration with wHbA<sub>1c</sub> 8.4% (68 mmol/mol) and 8.6% (70 mmol/mol), respectively. In contrast, one patient with wHbA<sub>1c</sub> 12.2% (110 mmol/mol) developed macroalbuminuria already after 9 years.


**CONCLUSIONS**

In this observational, population-based study, long-term wHbA<sub>1c</sub> was found to be a powerful biomarker for the development of laser-treated diabetic retinopathy and persistent macroalbuminuria in type 1 diabetes. No patient developed proliferative retinopathy or persistent macroalbuminuria below wHbA<sub>1c</sub> 7.6% (60 mmol/mol). The cumulative incidence of both complications increased steeply with increasing wHbA<sub>1c</sub> levels. Time to onset of complications was also influenced by HbA<sub>1c</sub> as in the primary prevention cohort of DCCT (5).

Even in very-well-controlled patients with wHbA<sub>1c</sub> ≤6.7% (50 mmol/mol), almost half of the patients had simplex retinopathy at follow-up. However, simplex retinopathy does not impair vision



**Figure 1**—HbA<sub>1c</sub> range for patients with various grades of retinopathy (A) and nephropathy (B) in an unselected population of patients with type 1 diabetes after 20–24 years of diabetes duration. Boundaries of box plots show quartiles, whiskers show nonoutlier range, unfilled circles show outliers, and asterisk shows extremes.



**Figure 2**—Prevalence of laser-treated proliferative retinopathy (A) and persistent macroalbuminuria (B) in an unselected population of patients with type 1 diabetes after 20–24 years of diabetes duration for different categories of long-term weighted mean HbA<sub>1c</sub>.

and is of no clinical importance, while proliferative retinopathy can cause blindness and should therefore be avoided. The same pattern applies to nephropathy, microalbuminuria being detected at all HbA<sub>1c</sub> levels. Microalbuminuria, as with background retinopathy, gives no clinical symptoms, even if it may be a predictor of persistent macroalbuminuria. However, ~30–60% will revert to normal, especially after improved glycemic control (21,22). The few patients in our study with good glycemic control but with microalbuminuria had all reverted to normal after ACE-inhibitor therapy or had low-grade microalbuminuria.

The DCCT concluded that there was no glycemic threshold for long-term complications since the relative risk reduction for microalbuminuria and progression of retinopathy was the same down to normal values. However, the absolute risk was very low below HbA<sub>1c</sub> 8.0% (64 mmol/mol) (23). Other authors have suggested a glycemic threshold of HbA<sub>1c</sub> of ~8–9% (65–75 mmol/mol) (24–26). A distinction should, however, be made between mild and severe diabetes complications. In the Linköping complications study, the risk for laser-treated retinopathy and persistent macroalbuminuria was


low below long-term mean HbA<sub>1c</sub> 8.4% (68 mmol/mol) and 9.3% (78 mmol/mol) for laser-treated retinopathy and persistent macroalbuminuria, respectively. However, HbA<sub>1c</sub> was not followed from diagnosis (9). In our present study, we found no cases of severe complications below HbA<sub>1c</sub> 7.6% (60 mmol/mol). If the aim is to avoid all microvascular complications, there seems to be no threshold, since both microalbuminuria and simple retinopathy occurred in patients with near-normal glycemic control. But if the aim is to prevent clinically significant complications, keeping HbA<sub>1c</sub> below 7.6% (60 mmol/mol) as a treatment target seems to prevent proliferative retinopathy and persistent macroalbuminuria, at least for 20 years.

The strength of our study lies in the fact that we followed an unselected population, in routine care, with complete follow-up during a long period of time. This has been possible due to the unique personal identity number that everyone has in Sweden. To our knowledge, this is the first long-term follow-up of diabetes complications and HbA<sub>1c</sub> measured from diabetes onset. The follow-up study after the DCCT, the Epidemiology of Diabetes Interventions and Complications (EDIC) study (27), could show a long-lasting effect of periods of good glycemic control on the incidence of retinopathy, often referred to as metabolic memory (28). The total glycemic exposure seems to be important for the development of microvascular complications, and Hirose et al. (29) recently demonstrated the importance of including HbA<sub>1c</sub> values right from diabetes onset.

However, there are limitations in this type of long observational study in clinical settings. For a few patients, there were periods with longer intervals between measurements and hence with unknown glycemic control. The HbA<sub>1c</sub> method changed during the follow-up period, but we were able to use conversion formulas to compensate for HbA<sub>1c</sub> analysis using different methods. As described above, the methods were, even in the early stages, of high precision and standardized against a national standard and also compared with the NGSP values (16,17). This makes it possible to compare our results with the recommendation of HbA<sub>1c</sub> targets after the DCCT study.

Since the follow-up period in this study was 20–24 years, the prognostic





**Figure 3**—Cumulative proportion of laser-treated retinopathy (A) and persistent macroalbuminuria (B) in an unselected population of patients with type 1 diabetes with different long-term weighted mean HbA<sub>1c</sub>. P values for pairwise comparisons between the group with lowest HbA<sub>1c</sub> and all other groups indicated in the figure.

importance of our study for longer diabetes durations is limited. In previous studies, the incidence of overt nephropathy has been reported to level off after 25 years of diabetes duration (10,11). This is in contrast to severe retinopathy, where the prevalence is still steadily increasing at the higher HbA<sub>1c</sub> levels after 25 years of diabetes duration (10). It is

therefore necessary to be cautious to extrapolate our results for longer diabetes duration than 20 years. It is also necessary to continue to perform very-long-term epidemiological studies.

It should be pointed out that other factors such as blood pressure, BMI, and lipids may influence the progression of diabetic microangiopathy. In our

present study, we found an association between these risk factors and microvascular complications in cross-sectional analysis. Even if there is an association, it is impossible to know if it is a cause or a consequence of the complications. It is also possible that early antihypertensive treatment could alter the level of long-term HbA<sub>1c</sub>, where severe diabetes complications occur, to a higher level. Quite a large proportion of the patients in our study had started antihypertensive treatment (mostly renin-angiotensin-aldosterone system inhibitors) without any signs of nephropathy (14%) or severe retinopathy (23%), and 28% used statins. Previous studies have shown that antihypertensive therapy can slow the progression of microalbuminuria to macroalbuminuria (30), but it is still unclear if early treatment can prevent the development of nephropathy and retinopathy, with conflicting results in different studies (31–33). The Renin Angiotensin System Study (RASS) suggested that the effect could also differ with the level of glycemic control (34). The use of lipid-lowering agents such as statins have also been found to alter the progression of both nephropathy and retinopathy. Even here the results from different studies so far are not conclusive (35,36). In our study, it is not possible to analyze further in order to see if these medications have influenced the impact of long-term mean HbA<sub>1c</sub> on the development of microvascular complications. Our results, however, must be viewed in the context of clinical guidelines for risk factor treatment.

Further analysis is also necessary to answer the question as to whether or not shorter periods of poor glycemic control are detrimental, especially during puberty. For all these reasons, it is necessary to be cautious when formulating distinct therapy goals.

**Clinical Implications**

The goal of treatment must be to prevent severe acute and chronic complications and to achieve as good a quality of life as possible. To reduce mortality, the most important factor is to avoid persistent macroalbuminuria, since the higher mortality in type 1 diabetes is mainly limited to patients with overt nephropathy (37–39). If the goal is to prevent persistent macroalbuminuria and proliferative retinopathy, wHbA<sub>1c</sub> below

~7.6% (60 mmol/mol) seems to be enough. This should be possible to achieve for most patients, even if it may be challenging in routine care. Mean HbA<sub>1c</sub> in the intensive treatment group in the DCCT study was 7.2% (55 mmol/mol), but in the follow-up EDIC study, carried out over a 10-year period, HbA<sub>1c</sub> rose to 8.0% (64 mmol/mol), which is in the same range as in our study.

In conclusion, we found a strong association between wHbA<sub>1c</sub> and microvascular complications. Keeping the average HbA<sub>1c</sub> below 7.6% (60 mmol/mol) seemed to be sufficient to prevent both persistent macroalbuminuria and severe retinopathy for at least up to 20 years and is a reasonable level to aim for in treatment of type 1 diabetes.

**Acknowledgments.** The authors are grateful to colleagues all over Sweden who helped with medical data and hospital records. Christina Ekenberg, research assistant, Linköping University, entered data from records into the computer and did a really wonderful job finding data from patients who had moved from the region.

**Funding.** This study was supported by the Swedish Child Diabetes Foundation (Barndiabetesfonden) and the Medical Research Council of Southeast Sweden (Forskningsrådet i Sydöstra Sverige).

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** M.N. and H.J.A. designed the study, did the literature research, made the statistical analysis, interpreted the data, and wrote the first draft of the article. M.A. and M.D. designed the study and evaluated the fundus photographs. M.F. made the statistical analysis and interpreted the data. J.L. designed the study, did the literature research, and interpreted the data. All authors reviewed and approved the final version of the report. M.N. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** Parts of this study were presented in abstract form at the 37th International Society for Pediatric and Adolescent Diabetes Annual Conference, Miami, FL, 19–22 October 2011, and at the 48th European Association for the Study of Diabetes Annual Meeting, Berlin, Germany, 1–5 October 2012.

## References

- Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. *Science* 1978;200:21–27
- Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. *Am J Cardiol* 1993;71:26B–31B
- Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic

retinopathy, nephropathy, and neuropathy: the Oslo study. *Br Med J (Clin Res Ed)* 1986;293:1195–1199

4. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. *Diabetologia* 1996;39:1483–1488

5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–986

6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405–412

7. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. *N Engl J Med* 1994;330:15–18

8. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J; Linköping Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes—the Linköping Diabetes Complications Study. *Diabetologia* 2004;47:1266–1272

9. Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications—the Linköping Diabetes Complications Study. *Pediatr Diabetes* 2009;10:168–176

10. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. *N Engl J Med* 1987;317:1390–1398

11. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark. *Diabetes* 1987;36:205–209

12. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnström K, Ludvigsson J; VISS Study Group. Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes. *Diabet Med* 2002;19:924–931

13. Porta M, Dalmasso P, Grassi G, et al. Prepubertal onset of type 1 diabetes and appearance of retinopathy. *Diabetes Metab* 2004;30:229–233

14. Laakso M, Cederberg H. Glucose control in diabetes: which target level to aim for? *J Intern Med* 2012;272:1–12

15. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. *Cochrane Database Syst Rev* 2014;2:CD009122

16. Hoelzel W, Weykamp C, Jeppsson JO, et al.; IFCC Working Group on HbA<sub>1c</sub> Standardization. IFCC reference system for measurement of hemoglobin A<sub>1c</sub> in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. *Clin Chem* 2004;50:166–174

17. Kullberg CE, Bergström A, Dinesen B, et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. *Diabetes Care* 1996;19:726–729

18. Treviño G. Consensus statement on the Worldwide Standardization of the Hemoglobin A<sub>1c</sub> Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation: response to the Consensus Committee. *Diabetes Care* 2007;30:e141

19. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. *BMJ* 1990;300:230–235

20. Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. *Invest Ophthalmol Vis Sci* 1981;21:1–226

21. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J. Glycemic control and prognosis in type I diabetic patients with microalbuminuria. *Diabetes Care* 1996;19:313–317

22. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. *Diabetologia* 1991;34:164–170

23. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. *Diabetes* 1996;45:1289–1298

24. Danne T, Weber B, Hartmann R, Enders I, Burger W, Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. *Diabetes Care* 1994;17:1390–1396

25. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. *N Engl J Med* 1995;332:1251–1255

26. Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. *N Engl J Med* 1995;332:1305–1306

27. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol* 2008;126:1707–1715

28. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med* 2000;342:381–389

29. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of retinopathy at 20 years after onset in younger-onset type 1 diabetes using mean metabolic memory-free HbA<sub>1c</sub> values: the importance of using HbA<sub>1c</sub> data of total, not partial, diabetes duration. *Diabetes Care* 2013;36:3812–3814

30. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. *Diabetologia* 1994;37:511–516

31. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. *Lancet* 2008;372:1394–1402
32. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. *Cochrane Database Syst Rev* 2012;12:CD004136
33. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. *N Engl J Med* 2009;361:40–51
34. Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML; Renin-Angiotensin System Study (RASS) group. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. *Diabetes Care* 2011;34:1838–1842
35. Matikainen N, Kahri J, Taskinen MR. Re-viewing statin therapy in diabetes—towards the best practise. *Prim Care Diabetes* 2010;4:9–15
36. Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? *Diabetes Res Clin Pract* 2005;68(Suppl. 2):S3–S14
37. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. *Diabetologia* 1983;25:496–501
38. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes* 2009;58:1651–1658
39. Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. *J Am Soc Nephrol* 2011;22:545–553